



• Statins are amongst the most commonly prescribed medications worldwide.
• Although statins are generally well tolerated, myotoxicity likely attributable to statin
therapy occurs in ~5% of patients1.
• Atorvastatin (ATV) is hydroxylated by CYP3A4
• Concomitant CYP3A4-inhibiting drug therapy is an established ATV
myotoxicity risk factor2.
• Rosuvastatin (RVT) is metabolised only to a minor extent, and mainly by CYP2C9 (~10%)3.
• P450 oxidoreductase (POR) is the major electron donor for all microsomal CYP enzymes4;
importantly, its effects on statin pharmacokinetics are unknown.
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• This work aimed to determine whether POR deficiency (knock out) alters statin
exposure using the selective hepatic POR null murine model (HRN).
1.) Hepatic microsomes from three wild-type (WT) and three HRN male mice 
were incubated (200μL final volume) for: 
a) 30 minutes with ATV (1-250μM) and; 
b) up to 120 minutes (ATV) or 240 minutes (RVT) at 20μM.
2.) Separately, three WT and three HRN male mice each received 30mg/Kg ATV
and 30mg/Kg RVT together via intraperitoneal injection (10mL/Kg).
• Serial blood samples were collected up to 24 hours onto dried blood spots.  
• The study was carried out in accordance with the Animal Scientific 
Procedures Act of 1986 and after a local ethics review.  
All bioanalysis was by liquid chromatography-mass spectrometry (Sciex 6500) 
using a method validated according to the FDA guidelines (2001).  
Pharmacokinetic analysis used the Real Statistics Resource Pack Excel add-in; 
statistical analysis was by Student’s t-test (p<0.05 designated as significant).
Methods
1.) These results demonstrate that POR deficiency is associated with:
• reduced in vitro ATV hydroxylation, likely reflecting decreased Cyp3a activity
• no difference in in vitro RVT levels, reflecting the minimal contribution of Cyp to RVT disposition.
2.) The in vivo increase of ATV lactone may represent a compensatory increase in non-POR dependent UDP-
glucuronyltransferase activity in HRN livers.
3.) The unexpected increase in hydroxy-ATV metabolites and RVT exposures in HRN mice in vivo suggests 
extra-hepatic CYP3A-mediated hydroxylation, an effect of transporters or potentially reduced hepatic uptake
due to the fatty liver that develops in HRN mice.
4.) Further research to characterise transporter protein expression in HRN mice is ongoing.  
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1.)  The in vitro liver microsome incubations demonstrated that POR deficiency is associated with:
• decreased ATV hydroxylation (Figure 1), 
• no effect on RVT hydroxylation (Figure 2).  
2.) A corresponding significant increase in ATV in vivo blood maximum concentration (Figure 3)
and exposure (Figures 3 &4) in HRN mice was observed.
3.) Unexpectedly, a significant increase in the in vivo blood maximum concentrations (Figure 3)
and exposures (Figures 3 & 4) of all ATV metabolites and RVT in HRN mice was also observed.
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Figure 2 Proportions of 20μM ATV and RVT 


























































































































































































































Figure 4 Individual  and mean analyte in vivo 
systemic exposures 
WT                       HRN WT                       HRN
